Richard E Pratley (Richard Pratley)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 34

Top Topics

Glycemic Control

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

BMJ open diabetes research & care

This page only lists publications with an associated author ORCID identifier.

Publications

Kenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, Florian M M Baeres, George Bakris, David M Charytan, David Z I Cherney, Gil Chernin, Ricardo Correa-Rotter, Janusz Gumprecht, Thomas Idorn, Giuseppe Pugliese, Ida Kirstine Bull Rasmussen, Søren Rasmussen, Ellen Burgess, Ekaterina Sokareva, Johannes F E Mann, Vlado Perkovic, Richard E Pratley
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. European heart journal (2024)
Ralph A DeFronzo, Richard J Auchus, Irina Bancos, Lawrence Blonde, Robert S Busch, John B Buse, James W Findling, Vivian A Fonseca, Juan P Frias, Oksana Hamidi, Yehuda Handelsman, Richard E Pratley, Julio Rosenstock, Iulia Cristina Tudor, Andreas G Moraitis, Daniel Einhorn
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ open 14 (7) (2024)
Brendon L Neuen, Robert A Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil V Badve, Katherine R Tuttle, Richard E Pratley, Ulagamadesan Venkatesan, Vlado Perkovic, Hiddo J Lambers Heerspink
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Circulation (2024)
Erin S LeBlanc, Anastassios G Pittas, Jason Nelson, Ranee Chatterjee, Neda Rasouli, Mary K Rhee, Richard E Pratley, Cyrus V Desouza, Lisa M Neff, Anne M Peters, Samuel Dagogo-Jack, Daniel S Hsia, null null
Racial differences in measures of glycemia in the Vitamin D and Type 2 Diabetes (D2d) Study: a secondary analysis of a randomized trial. BMJ open diabetes research & care 12 (1) (2024)
Ralph A DeFronzo, Richard J Auchus, Irina Bancos, Lawrence Blonde, Robert S Busch, John B Buse, James W Findling, Vivian A Fonseca, Juan P Frias, Oksana Hamidi, Yehuda Handelsman, Richard E Pratley, Julio Rosenstock, Iulia Cristina Tudor, Andreas G Moraitis, Daniel Einhorn
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ open 14 (7) (2024)
Erin S LeBlanc, Anastassios G Pittas, Jason Nelson, Ranee Chatterjee, Neda Rasouli, Mary K Rhee, Richard E Pratley, Cyrus V Desouza, Lisa M Neff, Anne M Peters, Samuel Dagogo-Jack, Daniel S Hsia, null null
Racial differences in measures of glycemia in the Vitamin D and Type 2 Diabetes (D2d) Study: a secondary analysis of a randomized trial. BMJ open diabetes research & care 12 (1) (2024)
Ralph A DeFronzo, Richard J Auchus, Irina Bancos, Lawrence Blonde, Robert S Busch, John B Buse, James W Findling, Vivian A Fonseca, Juan P Frias, Oksana Hamidi, Yehuda Handelsman, Richard E Pratley, Julio Rosenstock, Iulia Cristina Tudor, Andreas G Moraitis, Daniel Einhorn
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ open 14 (7) (2024)
Ralph A DeFronzo, Richard J Auchus, Irina Bancos, Lawrence Blonde, Robert S Busch, John B Buse, James W Findling, Vivian A Fonseca, Juan P Frias, Oksana Hamidi, Yehuda Handelsman, Richard E Pratley, Julio Rosenstock, Iulia Cristina Tudor, Andreas G Moraitis, Daniel Einhorn
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ open 14 (7) (2024)
Joseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, David Z I Cherney, Francesco Cosentino, Darren K McGuire, Richard E Pratley, Chih-Chin Liu, Nilo B Cater, Robert C Frederich, James P Mancuso, Christopher P Cannon
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease. Diabetes, obesity & metabolism (2023)
Ambarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, Christopher P Cannon, Robert C Frederich, David Z I Cherney, Samuel Dagogo-Jack, Richard E Pratley, Nilo B Cater, Ira Gantz, James P Mancuso, Darren K McGuire
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial. European heart journal (2023)
Ulagamadesan Venkatesan, Zhuoru Li, Chinthanie Ramasundarahettige, SeungJae Baek, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato Deláscio Lopes, Richard E Pratley, Julio Rosenstock, Naveed Sattar
Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. Circulation (2023)
Vanita R Aroda, Umut Erhan, Peter Jelnes, Juris J Meier, Morten Tind Abildlund, Richard E Pratley, Tina Vilsbøll, Mansoor Husain
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, obesity & metabolism (2023)
Sun H Kim, Ipsa Arora, Daniel S Hsia, William C Knowler, Erin S LeBlanc, Eleftherios Mylonakis, Richard E Pratley, Anastassios G Pittas
New-Onset Diabetes after COVID-19. The Journal of clinical endocrinology and metabolism (2023)
Daria Igudesman, Jamie L Crandell, Karen D Corbin, Dessi P Zaharieva, Ananta Addala, Joan M Thomas, Anna Casu, M Sue Kirkman, Teeranan Pokaprakarn, Michael C Riddell, Kyle S Burger, Richard E Pratley, Michael R Kosorok, David M Maahs, Elizabeth J Mayer-Davis, null null
Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results. Diabetes, obesity & metabolism (2022)
Ildiko Lingvay, Robert Bauer, James Baker-Knight, Jack Lawson, Richard E Pratley
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. The Journal of clinical endocrinology and metabolism 107 (5) (2022)
Vanita R Aroda, Lawrence Blonde, Richard E Pratley
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in endocrine & metabolic disorders 23 (5) (2022)
Richard E Pratley, Anders Gorst-Rasmussen
Indirect treatment comparisons: Choosing the right tool for the job. Diabetes, obesity & metabolism 24 (6) (2022)
Francesco Cosentino, Christopher P Cannon, Robert Frederich, David Z I Cherney, Samuel Dagogo-Jack, Richard E Pratley, James P Mancuso, Mario Maldonado, Nilo B Cater, Shuai Wang, Darren K McGuire
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial. Circulation 146 (8) (2022)
Richard E Pratley, Stephan Jacob, Seungjae Baek, Michael E Trautmann, Marcus Hompesch, OakPil Han, John Stewart, Christopher H Sorli, Alka Shaunik, Kun-Ho Yoon
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ open diabetes research & care 10 (1) (2022)
Klara R Klein, Edward Franek, Steven Marso, Thomas R Pieber, Richard E Pratley, Amoolya Gowda, Kajsa Kvist, John B Buse
Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE. BMJ open diabetes research & care 9 (2) (2021)
Carolyn Su Ping Lam, Chinthanie Ramasundarahettige, Kelley R H Branch, Naveed Sattar, Julio Rosenstock, Richard E Pratley, Stephano Del Prato, Renato Deláscio Lopes, Elisabeth Niemoeller, Nardev S Khurmi, SeungJae Baek, Hertzel C Gerstein
Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation (2021)
Richard E Pratley, Andrei-Mircea Catarig, Ildiko Lingvay, Adie Viljoen, Abby Paine, Jack Lawson, Barrie Chubb, Anders Gorst-Rasmussen, Nino Miresashvili
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes, obesity & metabolism 23 (11) (2021)
Samuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, Darren K McGuire, Francesco Cosentino, Weichung J Shih, Jie Liu, Robert Frederich, James P Mancuso, Annaswamy Raji, Ira Gantz
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ open diabetes research & care 9 (1) (2021)
Tina K Thethi, Anika Bilal, Richard E Pratley
Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes spectrum : a publication of the American Diabetes Association 34 (3) (2021)
Richard E Pratley, Samuel Dagogo-Jack, Bernard Charbonnel, Shrita Patel, Anne Hickman, Jie Liu, Lisa Tarasenko, Annpey Pong, Misoo C Ellison, Susan Huyck, Ira Gantz, Steven G Terra
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies. Diabetes, obesity & metabolism 22 (12) (2020)
Tina K Thethi, Richard E Pratley, Juris J Meier
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes, obesity & metabolism 22 (8) (2020)
Alan J Sinclair, Simon R Heller, Richard E Pratley, Ran Duan, Robert J Heine, Andreas Festa, Jacek Kiljański
Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. Diabetes, obesity & metabolism 22 (8) (2020)
Richard E Pratley, Vanita R Aroda, Andrei-Mircea Catarig, Ildiko Lingvay, Jörg Lüdemann, Emre Yildirim, Adie Viljoen
Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ open 10 (11) (2020)
Subodh Verma, Stephen C Bain, Tea Monk Fries, C David Mazer, Michael A Nauck, Richard E Pratley, Søren Rasmussen, Hans A Saevereid, Bernard Zinman, John B Buse
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes, obesity & metabolism 21 (7) (2019)
Richard E Pratley, Mansoor Husain, Ildiko Lingvay, Thomas R Pieber, Thomas Mark, Hans A Saevereid, Daniel Vega Møller, Bernard Zinman, null null
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovascular diabetology 18 (1) (2019)
Richard E Pratley, Jahoon Kang, Michael E Trautmann, Marcus Hompesch, OakPil Han, John Stewart, Christopher H Sorli, Stephan Jacob, Kun-Ho Yoon
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes, obesity & metabolism 21 (11) (2019)
Kirstine Brown-Frandsen, Scott S Emerson, Darren K McGuire, Thomas R Pieber, Neil R Poulter, Richard E Pratley, Bernard Zinman, Mattis F Ranthe, Randi Grøn, Martin Lange, Alan C Moses, Petra Örsy, John B Buse, null null
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). Diabetes, obesity & metabolism 21 (6) (2019)
William G Tharp, Dhananjay Gupta, Olga Sideleva, Carolyn F Deacon, Jens Juul Holst, Dariush Elahi, Richard E Pratley
Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. Diabetes 69 (2) (2019)
Richard E Pratley, Scott S Emerson, Edward Franek, Matthew P Gilbert, Steven P Marso, Darren K McGuire, Thomas R Pieber, Bernard Zinman, Charlotte T Hansen, Melissa V Hansen, Thomas Mark, Alan C Moses, John B Buse, null null
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes, obesity & metabolism 21 (7) (2019)